Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA2 | P42262 | 8/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.44 |
| ▸ | GRIA4 | P48058 | 13/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1875156 | 1.00 | GRIA2 (0.44) | GRIA2KCNH2GRIA4 | |
| SCHEMBL1875158 | 1.00 | GRIA2 (0.44) | GRIA2KCNH2GRIA4 | |
| SCHEMBL26144760 | 0.75 | GRIA4 (0.42) | GRIA2KCNH2GRIA4 | |
| SCHEMBL23733001 | 0.74 | GRIA2 (0.39) | GRIA2KCNH2GRIA4 | |
| SCHEMBL1873364 | 0.73 | GRIA2 (0.40) | GRIA2KCNH2GRIA4 | |
| SCHEMBL1873362 | 0.73 | GRIA2 (0.40) | GRIA2KCNH2GRIA4 | |
| SCHEMBL1873366 | 0.73 | GRIA2 (0.40) | GRIA2KCNH2GRIA4 | |
| SCHEMBL6240331 | 0.72 | GRIA4 (0.51) | GRIA2KCNH2GRIA4 | |
| SCHEMBL6242863 | 0.72 | GRIA4 (0.47) | GRIA2KCNH2GRIA4 | |
| SCHEMBL26144745 | 0.71 | GRIA2 (0.38) | GRIA2KCNH2GRIA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240051917-A1 | HETEROCYCLIC SULFONAMIDES, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF | BIOGEN MA INC (US) | 2024-02-15 | — | — | US | disclosed |
| US-20190100491-A1 | HETEROCYCLIC SULFONAMIDES, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF | PFIZER INC. | 2019-04-04 | — | — | US | disclosed |
| US-20170247360-A1 | HETEROCYCLIC SULFONAMIDES, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF | BIOGEN MA INC. | 2017-08-31 | — | — | US | disclosed |
| US-20160272625-A1 | HETEROCYCLIC SULFONAMIDES, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF | PFIZER INC. (US) | 2016-09-22 | — | — | US | disclosed |
| US-20140323502-A1 | HETEROCYCLIC SULFONAMIDES, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF | BIOGEN MA INC. | 2014-10-30 | — | — | US | disclosed |
| EP-2445883-B1 | HETEROCYCLIC SULFONAMIDES, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF | PFIZER (US) | 2014-08-13 | — | — | EP | disclosed |
| US-20120322823-A1 | HETEROCYCLIC SULFONAMIDES, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF | PFIZER INC. | 2012-12-20 | — | — | US | disclosed |
| US-8278457-B2 | Heterocyclic sulfonamides, uses and pharmaceutical compositions thereof | PFIZER INC. (US) | 2012-10-02 | — | — | US | disclosed |
| EP-2445883-A1 | HETEROCYCLIC SULFONAMIDES, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF | Pfizer Inc. (US) | 2012-05-02 | — | — | EP | disclosed |
| US-20110178165-A1 | TETRAHYDROFURANYL SULFONAMIDES AND PHARMACEUTICAL COMPOSITIONS THEREOF | PFIZER INC. | 2011-07-21 | — | — | US | disclosed |
| US-20110105533-A1 | Heterocyclic Sulfonamides, Uses and Pharmaceutical Compositions Thereof | PFIZER INC. | 2011-05-05 | — | — | US | disclosed |
| WO-2010150192-A1 | HETEROCYCLIC SULFONAMIDES, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF | PFIZER INC. (US) | 2010-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178165-A1 | TETRAHYDROFURANYL SULFONAMIDES AND PHARMACEUTICAL COMPOSITIONS THEREOF | STS, DHFR, SULT2A1 | GRIA2 1379/4885KCNH2 1649/4885GRIA4 769/4885 |
| US-20110105533-A1 | Heterocyclic Sulfonamides, Uses and Pharmaceutical Compositions Thereof | STS, SULT2A1, SULT1A1 | GRIA2 4145/4885KCNH2 1105/4885GRIA4 3983/4885 |
| US-20240051917-A1 | HETEROCYCLIC SULFONAMIDES, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF | STS, SULT2A1, SULT1A1 | GRIA2 4145/4885KCNH2 1105/4885GRIA4 3983/4885 |
| US-20120322823-A1 | HETEROCYCLIC SULFONAMIDES, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF | STS, SULT2A1, SULT1A1 | GRIA2 4145/4885KCNH2 1105/4885GRIA4 3983/4885 |
| US-20140323502-A1 | HETEROCYCLIC SULFONAMIDES, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF | STS, SULT2A1, SULT1A1 | GRIA2 4145/4885KCNH2 1105/4885GRIA4 3983/4885 |
| US-20160272625-A1 | HETEROCYCLIC SULFONAMIDES, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF | STS, SULT2A1, SULT1A1 | GRIA2 4145/4885KCNH2 1105/4885GRIA4 3983/4885 |
| US-20170247360-A1 | HETEROCYCLIC SULFONAMIDES, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF | STS, SULT2A1, SULT1A1 | GRIA2 4145/4885KCNH2 1105/4885GRIA4 3983/4885 |
| US-20190100491-A1 | HETEROCYCLIC SULFONAMIDES, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF | STS, SULT2A1, SULT1A1 | GRIA2 4145/4885KCNH2 1105/4885GRIA4 3983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.